[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
:: Volume 17, Issue 1 (1-2019) ::
Int J Radiat Res 2019, 17(1): 37-45 Back to browse issues page
PI3K and mTOR inhibitor, NVP-BEZ235, is more toxic than X-rays in prostate cancer cells
S. Maleka, A.M. Serafin, J.M. Akudugu
Abstract:   (2438 Views)
Background: Radiotherapy and adjuvant androgen deprivation therapy have historically been the first treatment choices for prostate cancer but treatment resistance often limits the capacity to effectively manage the disease. Therefore, alternative therapeutic approaches are needed. Here, the efficacies of radiotherapy and targeting the pro-survival cell signaling components epidermal growth factor receptor (EGFR), phosphoinositide 3-kinase (PI3K), and mammalian target of rapamycin (mTOR), with their respective inhibitors are compared. Materials and Methods: The cytotoxic effects of inhibitors of PI3K and mTOR (NVP-BEZ235) and EGFR (AG-1478), and X-rays, were evaluated in prostate cell lines (LNCaP: cancer; DU145: cancer; BPH-1: benign prostatic hyperplasia; 1542N: apparently “normal”) using a colony forming assay. The cells were exposed to a range of X-ray doses or varying concentrations of the inhibitors, to obtain cell survival curves from which relative sensitivities (RS) of the tumor cell lines were derived as the ratio of their sensitivities to that of the “normal” cell line. Results: The LNCaP cells trended to be more sensitive to X-rays and AG-1478 exposure than 1542N cells, with RS-values of 1.65±0.48 (P=0.1644) and 1.37±0.22 (P=0.0822), respectively. NVP-BEZ235 emerged as very cytotoxic in all tumor cell lines, yielding RS-values of 3.69±0.83 (DU145; P=0.0025), 8.80±1.73 (LNCaP; P<0.0001), and 8.76±1.70 (BPH-1; P=0.0011). Conclusion: These findings demonstrated that targeted therapy, specifically that using NVP-BEZ235, might result in a more effective treatment modality for prostate cancer than conventional radiotherapy.
Keywords: Radiotherapy, targeted therapy, prostate cancer, PI3K, mTOR, EGFR.
Full-Text [PDF 1988 kb]   (440 Downloads)    
Type of Study: Original Research | Subject: Radiation Biology
Add your comments about this article
Your username or Email:


XML     Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Maleka S, Serafin A, Akudugu J. PI3K and mTOR inhibitor, NVP-BEZ235, is more toxic than X-rays in prostate cancer cells . Int J Radiat Res. 2019; 17 (1) :37-45
URL: http://ijrr.com/article-1-2456-en.html

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 17, Issue 1 (1-2019) Back to browse issues page
International Journal of Radiation Research
Persian site map - English site map - Created in 0.04 seconds with 32 queries by YEKTAWEB 4355